A federal appeals court will hear arguments about whether companies can patent genes on July 20. The American Civil Liberties Union has challenged Myriad Genetics’ patents on the BRCA 1 and BRCA2 genes, which affect the risk of breast and ovarian cancer. The Supreme Court sent the case back to the Court of Appeals for the Federal Circuit last month.
The ACLU pointed out that studies have shown a new class of cancer drugs called PARP inhibitors can help cancer patients with specific BRCA mutations.”However, the FDA (Food and Drug Administration) will not approve the drugs unless all accompanying diagnostic tests are also FDA-approved. Myriad’s tests – like most genetic tests – have not been approved by the FDA,” the ACLU said in a statement.
“You’d think that Myriad would submit to FDA approval so that these drugs can make their way to the people that need them, but they have not. As a consequence,Myriad’s patents are preventing women from learning if they have the genes and preventing them from getting the treatment they need if they do.”
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Aggregated News
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
A Mexican standoff with the United States turned into a Mexican smack-down this month with the release of Mexico’s formal rebuttal to US efforts to overturn limits Mexico has ordered on the use of genetically modified (GM) corn and the...
The U.S. government must move “quickly and decisively” to avert substantial national security risks stemming from artificial intelligence (AI) which could, in the worst case, cause an “extinction-level threat to the human species,” says a report commissioned by the U.S...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.
